RIVASTIGMINE
( DrugBank: Rivastigmine / KEGG DRUG: Rivastigmine tartrate, Rivastigmine )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 5 | Progressive supranuclear palsy | 3 |
| 6 | Parkinson disease | 13 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 2 |
5. Progressive supranuclear palsy
Clinical trials : 120 / Drugs : 141 - (DrugBank : 36) / Drug target genes : 68 - Drug target pathways : 112
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
6. Parkinson disease
Clinical trials : 2,817 / Drugs : 2,606 - (DrugBank : 348) / Drug target genes : 185 - Drug target pathways : 205
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,898 / Drugs : 2,785 - (DrugBank : 360) / Drug target genes : 265 - Drug target pathways : 239
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|